Shire’s Treatment for Chronic Lung Disease in Premature Infants Fast Tracked by FDA

The FDA has fast tracked Shire’s candidate for chronic lung disease in extremely premature infants from Phase 2 of clinical development.

The FDA has fast tracked Shire’s candidate, SHP607, for the treatment of chronic lung disease based on preclinical data, the results of Phase I and II studies so far, and a lack of treatments currently available. Howard Mayer, Shire’s Head of R&D said: “There are no approved treatment options for chronic lung disease for premature infants, and we are aiming to change that.” It must be noted that despite this being a positive step, there are no guarantees that it will ultimately be approved.

SHP607 is a recombinant human version of the insulin-like growth factor 1 (IGF-1) protein and its abundant binding protein, IGF binding protein-3 (IGFBP-3). IGF-1 is important in the development of the fetus, but in premature infants, levels of IGF-1 decrease before 28 weeks, which increases the risk of complications. Around 60% of extremely premature infants experience complications, and severe complications can have life-long effects. Current therapies focus on controlling symptoms, so Shire’s treatment offers new hope of remedying the condition.


Image – Aynur_sib / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.